CEL-SCI

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Urban Outfitters

ATCH

BTOG

DGLY

KDLY

LTRY

LUMN

MANU

NINE

NVTS

SEDG

SNOW

UPXI

URBN

VSTE

VTAK

WHLR

Longevity Health Holdings, Inc. - Common Stock

XAGE

Urban Outfitters sube tras superar expectativas de beneficios; otras acciones como Navitas y Snowflake también destacan en el premercado.

Acciones de Urban Outfitters (URBN) se disparan un 18%; Aquí están 20 acciones que se mueven en el premercado

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

Equities

Offerings

Small Cap

Acciones de Cel-Sci Corporation (CVM) caen tras anunciar oferta pública

CEL-SCI Corp

Morgan Stanley ETF Trust Calvert US Mid-Cap Core Responsible Index ETF

Sila Realty Trust Inc Ordinary Shares - Class A

Sila Realty Trust Inc Ordinary Shares - Class T

Press Releases

CEL-SCI Announces Closing of Public Offering

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

CEL-SCI Announces Proposed Public Offering

CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Announces Closing of $10 Million Public Offering

ABVC BioPharma

Adicet Bio

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

AlphaTON Capital

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

CervoMed

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

MAIA Biotechnology

MediciNova

OS Therapies

PMV Pharma

Plus Therapeutics

Sutro Biopharma

X4 Pharmaceuticals

EF Hutton

Comments

CEL-SCI

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL